-
EP4319771
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4319771
| EP4319771 - TREATMENT OF CANCER WITH NK CELLS AND A HER2 TARGETED ANTIBODY [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 12.01.2024 Database last updated on 03.09.2024 | |
| Former | The international publication has been made Status updated on 14.10.2022 | Most recent event Tooltip | 14.06.2024 | Change: Validation states | published on 17.07.2024 [2024/29] | 14.06.2024 | Change - extension states | published on 17.07.2024 [2024/29] | Applicant(s) | For all designated states Artiva Biotherapeutics, Inc. 5505 Morehouse Drive, Suite 100 San Diego, CA 92121 / US | For all designated states GC Cell Corporation 131-1, Ihyeon-ro 30 beon-gil Giheung-gu Yongin-si Gyeonggi-do 16924 / KR | [2024/07] | Inventor(s) | 01 /
KIM, Yusun Yongin-si Gyeonggi-do 16924 / KR | 02 /
CHO, Sungyoo Yongin-si Gyeonggi-do 16924 / KR | 03 /
HWANG, Yu Kyeong Yongin-si Gyeonggi-do 16924 / KR | 04 /
MIN, Bokyung Yongin-si Gyeonggi-do 16924 / KR | 05 /
YANG, Bitna Yongin-si Gyeonggi-do 16924 / KR | 06 /
KIM, Eunji Yongin-si Gyeonggi-do 16924 / KR | 07 /
FLYNN, Peter Cardiff by the Sea, California 92007 / US | 08 /
LITTEN, Jason B. Poway, California 92064 / US | 09 /
FARRELL, Thomas James La Jolla, California 92037 / US | 10 /
LIM, John Kin Chuan San Diego, California 92130 / US | 11 /
MANDAL, Mili San Diego, California 92130 / US | [2024/07] | Representative(s) | Fish & Richardson P.C. Highlight Business Towers Mies-van-der-Rohe-Straße 8 80807 München / DE | [2024/07] | Application number, filing date | 22785376.9 | 06.04.2022 | [2024/07] | WO2022US23684 | Priority number, date | US202163172414P | 08.04.2021 Original published format: US 202163172414 P | US202163290359P | 16.12.2021 Original published format: US 202163290359 P | [2024/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022216831 | Date: | 13.10.2022 | Language: | EN | [2022/41] | Type: | A1 Application with search report | No.: | EP4319771 | Date: | 14.02.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 13.10.2022 takes the place of the publication of the European patent application. | [2024/07] | Search report(s) | International search report - published on: | US | 13.10.2022 | Classification | IPC: | A61K35/17, A61K39/395, A61P35/00, C07K16/28 | [2024/07] | CPC: |
A61P35/00 (EP,KR,US);
A61K35/17 (KR);
A61K2239/49 (EP,US);
A61K2239/59 (EP,US);
A61K31/664 (US);
A61K31/7076 (US);
A61K38/2013 (KR,US);
A61K39/395 (EP);
A61K39/39558 (KR);
A61K39/4613 (EP,US);
A61K39/464406 (EP,US);
A61K45/06 (EP);
C07K16/32 (EP,KR,US);
C12N5/0646 (KR,US);
A61K2039/505 (KR,US);
A61K2039/545 (KR);
A61K2239/38 (US);
A61K2239/51 (US);
A61K2300/00 (KR);
C07K16/2809 (EP);
C07K2317/24 (EP);
| C-Set: |
A61K39/395, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/07] | Title | German: | BEHANDLUNG VON KREBS MIT NK-ZELLEN UND EINEM AUF HER2 GERICHTETEN ANTIKÖRPER | [2024/07] | English: | TREATMENT OF CANCER WITH NK CELLS AND A HER2 TARGETED ANTIBODY | [2024/07] | French: | TRAITEMENT DU CANCER PAR DES CELLULES NK ET UN ANTICORPS CIBLANT L'HER2 | [2024/07] | Entry into regional phase | 06.11.2023 | National basic fee paid | 06.11.2023 | Search fee paid | 06.11.2023 | Designation fee(s) paid | 06.11.2023 | Examination fee paid | Examination procedure | 06.11.2023 | Examination requested [2024/07] | 16.05.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 22.03.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]US2018344828 (WOOD LAUREN V [US], et al); | [Y]US2019175592 (WEISS MICHAEL S [US], et al); | [A]US2019336533 (HWANG YU KYEONG [KR], et al); | [XY]WO2019222293 (INDAPTA THERAPEUTICS INC [US]); |